Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
16 Leser
Artikel bewerten:
(0)

Food Allergy Pipeline Review H2 2014 Market Research Report

DALLAS, January 6, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Food Allergy - Pipeline Review, H2 2014" of 39 pages to the allergy therapeutics section of life sciences intelligence collection in its online business research and data library.

The Food Allergy Pipeline Review, H2 2014 research report provides an overview of the Food Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Food Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Food Allergy and special features on late-stage and discontinued projects. Complete report is available at http://www.rnrmarketresearch.com/food-allergy-pipeline-review-h2-2014-market-report.html .

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scopeof the Food Allergy Pipeline Review, H2 2014 research report covers: a snapshot of the global therapeutic landscape of Food Allergy; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Food Allergy and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; A review of the Food Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Food Allergy pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products.

Companies discussed in this food allergy therapeutic research include Allakos Inc., Biomay AG, Sanofi and Selecta Biosciences, Inc. Drug profiles for E-3.56, Epsi-Gam, fish hypoallergenic vaccine, Monoclonal Antibodies for Allergy and Inflammatory Diseases, Pru p 3 Allergen for Peach Allergy, Pru p 3.02, Pru p 3.03 and Vaccine for Food Allergy are covered in this report. Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=254190 .

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Reasons to buy one or more of these therapeutic pipeline review reports include:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Food Allergy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Food Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on the allergy therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/allergy-therapeutics .

About Us:
RnRMarketResearch.com is a digital library of 500,000+ syndicated market research reports and in-depth studies of 5000+ micro markets. We provide reports by 100+ publishers on a range of categories and industries.

Contact:

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441

sales@rnrmarketresearch.com

Connect with Us:

G+ / Google Plus:https://plus.google.com/104156468549256253075/posts

Twitter:https://twitter.com/RnRMR

Facebook:https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds:http://www.rnrmarketresearch.com/feed


Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.